Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes

Barbara Testoni, David Durantel, Fanny Lebossé, Judith Fresquet, François Helle, Francesco Negro, Maria Francesca Donato, Massimo Levrero, Fabien Zoulim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objectives Caveats in the understanding of ribavirin (RBV) mechanisms of action has somehow prevented the development of better analogues able to further improve its therapeutic contribution in interferon (IFN)-based and direct antiviral agent-based regimens for chronic HCV or other indications. Here, we describe a new mechanism by which RBV modulates IFN-stimulated genes (ISGs) and contributes to restore hepatic immune responsiveness. Design RBV effect on ISG expression was monitored in vitro and in vivo, that is, in non-transformed hepatocytes and in the liver of RBV mono-treated patients, respectively. Modulation of histone modifications and recruitment of histone-modifying enzymes at target promoters was analysed by chromatin immunoprecipitation in RBV-treated primary human hepatocytes and in patients' liver biopsies. Results RBV decreases the mRNA levels of several abnormally preactivated ISGs in patients with HCV, who are non-responders to IFN therapy. RBV increases G9a histone methyltransferase recruitment and histone-H3 lysine-9 dimethylation/trimethylation at selected ISG promoters in vitro and in vivo. G9a pharmacological blockade abolishes RBV-induced ISG downregulation and severely impairs RBV ability to potentiate IFN antiviral action and induction of ISGs following HCV infection of primary human hepatocytes. Conclusions RBV-induced epigenetic changes, leading to decreased ISG expression, restore an IFN-responsive hepatic environment in patients with HCV, which may also prove useful in IFN-free regimens.

Original languageEnglish
Pages (from-to)672-682
Number of pages11
JournalGut
Volume65
Issue number4
DOIs
Publication statusPublished - 2016

Fingerprint

Ribavirin
Epigenomics
Interferons
Liver
Genes
Hepatocytes
Histones
Antiviral Agents
Histone Code
Gene Expression
Chromatin Immunoprecipitation
Lysine
Down-Regulation
Pharmacology
Biopsy
Messenger RNA

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Testoni, B., Durantel, D., Lebossé, F., Fresquet, J., Helle, F., Negro, F., ... Zoulim, F. (2016). Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes. Gut, 65(4), 672-682. https://doi.org/10.1136/gutjnl-2014-309011

Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes. / Testoni, Barbara; Durantel, David; Lebossé, Fanny; Fresquet, Judith; Helle, François; Negro, Francesco; Donato, Maria Francesca; Levrero, Massimo; Zoulim, Fabien.

In: Gut, Vol. 65, No. 4, 2016, p. 672-682.

Research output: Contribution to journalArticle

Testoni, B, Durantel, D, Lebossé, F, Fresquet, J, Helle, F, Negro, F, Donato, MF, Levrero, M & Zoulim, F 2016, 'Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes', Gut, vol. 65, no. 4, pp. 672-682. https://doi.org/10.1136/gutjnl-2014-309011
Testoni, Barbara ; Durantel, David ; Lebossé, Fanny ; Fresquet, Judith ; Helle, François ; Negro, Francesco ; Donato, Maria Francesca ; Levrero, Massimo ; Zoulim, Fabien. / Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes. In: Gut. 2016 ; Vol. 65, No. 4. pp. 672-682.
@article{06cbb0f341cf466e95de8788b9a04e56,
title = "Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes",
abstract = "Objectives Caveats in the understanding of ribavirin (RBV) mechanisms of action has somehow prevented the development of better analogues able to further improve its therapeutic contribution in interferon (IFN)-based and direct antiviral agent-based regimens for chronic HCV or other indications. Here, we describe a new mechanism by which RBV modulates IFN-stimulated genes (ISGs) and contributes to restore hepatic immune responsiveness. Design RBV effect on ISG expression was monitored in vitro and in vivo, that is, in non-transformed hepatocytes and in the liver of RBV mono-treated patients, respectively. Modulation of histone modifications and recruitment of histone-modifying enzymes at target promoters was analysed by chromatin immunoprecipitation in RBV-treated primary human hepatocytes and in patients' liver biopsies. Results RBV decreases the mRNA levels of several abnormally preactivated ISGs in patients with HCV, who are non-responders to IFN therapy. RBV increases G9a histone methyltransferase recruitment and histone-H3 lysine-9 dimethylation/trimethylation at selected ISG promoters in vitro and in vivo. G9a pharmacological blockade abolishes RBV-induced ISG downregulation and severely impairs RBV ability to potentiate IFN antiviral action and induction of ISGs following HCV infection of primary human hepatocytes. Conclusions RBV-induced epigenetic changes, leading to decreased ISG expression, restore an IFN-responsive hepatic environment in patients with HCV, which may also prove useful in IFN-free regimens.",
author = "Barbara Testoni and David Durantel and Fanny Leboss{\'e} and Judith Fresquet and Fran{\cc}ois Helle and Francesco Negro and Donato, {Maria Francesca} and Massimo Levrero and Fabien Zoulim",
year = "2016",
doi = "10.1136/gutjnl-2014-309011",
language = "English",
volume = "65",
pages = "672--682",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "4",

}

TY - JOUR

T1 - Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes

AU - Testoni, Barbara

AU - Durantel, David

AU - Lebossé, Fanny

AU - Fresquet, Judith

AU - Helle, François

AU - Negro, Francesco

AU - Donato, Maria Francesca

AU - Levrero, Massimo

AU - Zoulim, Fabien

PY - 2016

Y1 - 2016

N2 - Objectives Caveats in the understanding of ribavirin (RBV) mechanisms of action has somehow prevented the development of better analogues able to further improve its therapeutic contribution in interferon (IFN)-based and direct antiviral agent-based regimens for chronic HCV or other indications. Here, we describe a new mechanism by which RBV modulates IFN-stimulated genes (ISGs) and contributes to restore hepatic immune responsiveness. Design RBV effect on ISG expression was monitored in vitro and in vivo, that is, in non-transformed hepatocytes and in the liver of RBV mono-treated patients, respectively. Modulation of histone modifications and recruitment of histone-modifying enzymes at target promoters was analysed by chromatin immunoprecipitation in RBV-treated primary human hepatocytes and in patients' liver biopsies. Results RBV decreases the mRNA levels of several abnormally preactivated ISGs in patients with HCV, who are non-responders to IFN therapy. RBV increases G9a histone methyltransferase recruitment and histone-H3 lysine-9 dimethylation/trimethylation at selected ISG promoters in vitro and in vivo. G9a pharmacological blockade abolishes RBV-induced ISG downregulation and severely impairs RBV ability to potentiate IFN antiviral action and induction of ISGs following HCV infection of primary human hepatocytes. Conclusions RBV-induced epigenetic changes, leading to decreased ISG expression, restore an IFN-responsive hepatic environment in patients with HCV, which may also prove useful in IFN-free regimens.

AB - Objectives Caveats in the understanding of ribavirin (RBV) mechanisms of action has somehow prevented the development of better analogues able to further improve its therapeutic contribution in interferon (IFN)-based and direct antiviral agent-based regimens for chronic HCV or other indications. Here, we describe a new mechanism by which RBV modulates IFN-stimulated genes (ISGs) and contributes to restore hepatic immune responsiveness. Design RBV effect on ISG expression was monitored in vitro and in vivo, that is, in non-transformed hepatocytes and in the liver of RBV mono-treated patients, respectively. Modulation of histone modifications and recruitment of histone-modifying enzymes at target promoters was analysed by chromatin immunoprecipitation in RBV-treated primary human hepatocytes and in patients' liver biopsies. Results RBV decreases the mRNA levels of several abnormally preactivated ISGs in patients with HCV, who are non-responders to IFN therapy. RBV increases G9a histone methyltransferase recruitment and histone-H3 lysine-9 dimethylation/trimethylation at selected ISG promoters in vitro and in vivo. G9a pharmacological blockade abolishes RBV-induced ISG downregulation and severely impairs RBV ability to potentiate IFN antiviral action and induction of ISGs following HCV infection of primary human hepatocytes. Conclusions RBV-induced epigenetic changes, leading to decreased ISG expression, restore an IFN-responsive hepatic environment in patients with HCV, which may also prove useful in IFN-free regimens.

UR - http://www.scopus.com/inward/record.url?scp=84932625135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932625135&partnerID=8YFLogxK

U2 - 10.1136/gutjnl-2014-309011

DO - 10.1136/gutjnl-2014-309011

M3 - Article

VL - 65

SP - 672

EP - 682

JO - Gut

JF - Gut

SN - 0017-5749

IS - 4

ER -